Zodasiran is named as an intervention in 2 current clinical trials in our USA, Germany, France, Spain, Belgium, Sweden, Austria, Czechia, Turkey, Canada, Brazil, Japan, Australia, Israel and China registers. None are recruiting at the moment. All registered phases are Phase 3. The sponsor with the most trials is Arrowhead Pharmaceuticals (1). The most-studied condition is Homozygous Familial Hypercholesterolemia. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Zodasiran. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)
2025-523662-24-00 · Cardiovascular Diseases
|
Phase 3 | Ongoing | Arrowhead Pharmaceuticals Inc | Netherlands, Denmark, Norway + 2 more |
|
Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE)
2025-521792-31-01 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Ongoing | Arrowhead Pharmaceuticals Inc | Greece, France, Belgium + 7 more |
| Lead sponsor | Trials |
|---|---|
| Arrowhead Pharmaceuticals | 1 |
| Visirna Therapeutics HK Limited | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our USA, Germany, France, Spain, Belgium, Sweden, Austria, Czechia, Turkey, Canada, Brazil, Japan, Australia, Israel and China registers name Zodasiran (also registered as ARO-ANG3) as a drug or biological intervention, as of the registry sync on 3 October 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Arrowhead Pharmaceuticals (1) and Visirna Therapeutics HK Limited (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zodasiran works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zodasiran works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zodasiran (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
